Maria Tzefos

Summary

Affiliation: Wingate University
Country: USA

Publications

  1. doi request reprint 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy
    Maria Tzefos
    Wingate University School of Pharmacy, Wingate, NC 28174, USA
    J Clin Lipidol 5:450-9. 2011
  2. doi request reprint Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults
    Maria Tzefos
    Cabarrus Family Medicine, Harrisburg, NC, USA
    Ann Pharmacother 46:68-78. 2012
  3. doi request reprint Fesoterodine for the treatment of overactive bladder
    Maria Tzefos
    School of Pharmacy, Wingate University, Wingate, NC 28174, USA
    Ann Pharmacother 43:1992-2000. 2009
  4. doi request reprint Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus
    Maria Tzefos
    School of Pharmacy, Wingate University, NC 28174, USA
    Ann Pharmacother 44:1294-300. 2010
  5. doi request reprint Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors
    Cassie L Boland
    School of Pharmacy, Wingate University, Wingate, NC, USA
    Ann Pharmacother 47:490-505. 2013

Collaborators

Detail Information

Publications5

  1. doi request reprint 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy
    Maria Tzefos
    Wingate University School of Pharmacy, Wingate, NC 28174, USA
    J Clin Lipidol 5:450-9. 2011
    ..To review efficacy and safety data of 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) in adult patients with chronic liver disease...
  2. doi request reprint Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults
    Maria Tzefos
    Cabarrus Family Medicine, Harrisburg, NC, USA
    Ann Pharmacother 46:68-78. 2012
    ..To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM)...
  3. doi request reprint Fesoterodine for the treatment of overactive bladder
    Maria Tzefos
    School of Pharmacy, Wingate University, Wingate, NC 28174, USA
    Ann Pharmacother 43:1992-2000. 2009
    ..To review pharmacologic, pharmacokinetic, efficacy, and safety data for fesoterodine and determine its role in the treatment of overactive bladder...
  4. doi request reprint Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus
    Maria Tzefos
    School of Pharmacy, Wingate University, NC 28174, USA
    Ann Pharmacother 44:1294-300. 2010
    ..To evaluate the efficacy and tolerability of combination glucagon-like peptide-1 (GLP-1) analogs and insulin in the management of type 2 diabetes mellitus (T2DM) in adults...
  5. doi request reprint Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors
    Cassie L Boland
    School of Pharmacy, Wingate University, Wingate, NC, USA
    Ann Pharmacother 47:490-505. 2013
    ....